I n t e r v e n t i o n Adults were allocated to MM (n = 91) for 14 months or to 120 days of methadoneassisted maintenance and 60 days of methadone-assisted detoxification with intensive psychosocial services and 8 months of aftercare (M180) (n = 88). The initial methadone dose was 30 mg/d, which was increased to 80 mg/d within the first 3 treatment weeks. The maximum dose was 100 mg/d, which was reached by day 44.
M a i n o u t c o m e m e a s u r e s
The main outcome was treatment retention. The following outcomes were also assessed but had < 80% follow-up: opioid and cocaine use (assessed by self-report and urine screening test); HIV risk behaviors (Risk of AIDS Behavior scale score); and function in employment, drug use, alcohol use, legal, family, and psychiatric problem areas (Addiction Severity Index).
M a i n r e s u l t s
Analysis was by intention to treat. Patients in the MM group remained in treatment longer than did patients in the M180 group (median 439 d, 95% CI 413 to 441 vs 174 d, CI 161 to 181; P < 0.001). More patients were discharged from treatment for noncompliance in the M180 group than in the MM group (Table) .
C o n c l u s i o n
In adults with opioid dependence, treatment retention was greater for methadone maintenance than for methadoneassisted detoxification plus intensive psychosocial services. 
C o m m e n t a r y
In this study by Sees and colleagues, MM is compared with a detoxification package involving an identical methadone dose followed by detoxification and aftercare (M180). MM resulted in better treatment retention than did M180 and lowered HIV risk and legal status scores, which is no doubt a reflection of increased illicit drug use in M180. Treatment retention in the M180 group was adversely affected by receipt of an intensive psychosocial intervention and rapid opiate detoxification in a context where most patients did not want to detoxify. M180 had about 10% to 15% more discharges than did MM during the first 4 months (even though the medication used during this period was identical in both groups), presumably because of the more stringent attendance requirements (1.25 vs 3 to 4 hours per wk). The detoxification phase in M180 was 60 days and involved a weekly 10-mg methadone reduction from an average starting dose of 85-mg methadone, which is likely to have generated prolonged mildto-moderate opiate withdrawal symptoms. Only 50% of patients in this group reported wanting to stop illicit opiate use in addition to their methadone, and no doubt even fewer would have wanted complete opioid detoxification.
Failure to attend therapy sessions resulted in discharge, but continued use of heroin or other illicit drugs did not. Indeed, 60% to 70% of participants continued to use illicit opiates (even when on maximal methadone treatment in both groups), which increased to about 90% after methadone termination in the M180 group. 50% to 70% of patients also continued to use cocaine during the study. These high rates suggest that the psychosocial intervention was insufficiently targeted at this clinically important goal.
For clinicians, this study shows the importance of targeting illicit drug use with a psychosocial intervention, the dangers of compulsory intensive psychosocial treatments, and the necessity that those who undergo therapeutic detoxification must really want to do so and are prepared to tolerate the level of suffering required. Treatment retention 74% 55% 35% (8 to 71) 6 (4 to 20) ‡Abbreviations defined in Glossary; RBI, NNT, and CI calculated from data in article.
